Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May 20:152:797-809.
doi: 10.1016/j.freeradbiomed.2020.01.177. Epub 2020 Feb 1.

The peroxisomal fatty acid transporter ABCD1/PMP-4 is required in the C. elegans hypodermis for axonal maintenance: A worm model for adrenoleukodystrophy

Affiliations

The peroxisomal fatty acid transporter ABCD1/PMP-4 is required in the C. elegans hypodermis for axonal maintenance: A worm model for adrenoleukodystrophy

Andrea Coppa et al. Free Radic Biol Med. .

Abstract

Adrenoleukodystrophy is a neurometabolic disorder caused by a defective peroxisomal ABCD1 transporter of very long-chain fatty acids (VLCFAs). Its pathogenesis is incompletely understood. Here we characterize a nematode model of X-ALD with loss of the pmp-4 gene, the worm orthologue of ABCD1. These mutants recapitulate the hallmarks of X-ALD: i) VLCFAs accumulation and impaired mitochondrial redox homeostasis and ii) axonal damage coupled to locomotor dysfunction. Furthermore, we identify a novel role for PMP-4 in modulating lipid droplet dynamics. Importantly, we show that the mitochondria targeted antioxidant MitoQ normalizes lipid droplets size, and prevents axonal degeneration and locomotor disability, highlighting its therapeutic potential. Moreover, PMP-4 acting solely in the hypodermis rescues axonal and locomotion abnormalities, suggesting a myelin-like role for the hypodermis in providing essential peroxisomal functions for the nematode nervous system.

Keywords: Axonal degeneration; Hypodermis; Lipid droplets; Mitochondria redox imbalance; Peroxisomes; X-linked adrenoleukodystrophy.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors declare no conflict of interest.

Figures

Figure 1
Figure 1. C. elegans pmp-4(ok396) mutants recapitulate the main hallmarks observed in X-ALD.
(A) PMP-4 and PMP-4::GFP protein levels in wild-type (WT), pmp-4(ok396) and pmp-4(ok396) animals expressing PMP-4::GFP under the control of the pmp-4 promoter (pmp-4(ok396); Ex042 [Ppmp-4::pmp-4::gfp]) at the L4 larval stage. β-actin was used as a loading control (bottom panel) (n=4 pools of worms by condition). (B-C) Immunofluorescence staining of formaldehyde-fixed (B) WT and (C) pmp-4(ok396) worms incubated with polyclonal anti-PMP-4 (red) and counterstained with DAPI (blue) at the L4 larval stage. The posterior part of the worm is depicted. I=intestine and H=hypodermis. Scale = 10μm. (D) Lysophosphatidylcholine fatty acid levels (LPC-20:0, LPC-22:0, LPC-24:0 and LPC-26:0) of L4 worm lysates of WT (n=12), pmp-4(ok396)(n=10) and daf-22(ok693) animals (n=6). The daf-22(ok693) mutant was used as a positive control. (E) Tissular expression of GFP under the control of the pmp-4 promoter (Ex001 [Ppmp-4::gfp]) in the intestine=I and hypodermis=H at L4. The worm is oriented head to the left, dorsal face-up. The same results were obtained by three independent transgenic lines. Scale = 10μm. (F-I) The construct containing PMP-4::GFP under the control of the pmp-4 promoter was injected into the strain labelling peroxisomes with RFP in the intestine (hjIs37 [Pvha-6p::rfp::PTS1]; Ex048 [Ppmp-4::pmp-4::gfp]). Images of (F) RFP::PTS1 and (G) PMP-4::GFP staining. (H) Merge of images F and G. In yellow, colocalization of RFP::PTS-1 with PMP-4::GFP. (I) DIC-Nomarsky pictures corresponding to the fluorescence images (n=30). (J-M) The constructs containing GFP::PTS1 under the control of a specific hypodermal promoter (Pdpy-7) and PMP-4::mCherry under the control of the pmp-4 promoter were coinjected in the N2 strain (Ex095 [Pdpy-7::gfp::PTS1 + Ppmp-4::pmp-4::mCherry]). Here, the peroxisomes are labelled with GFP in the hypodermis. Images of (J) GFP::PTS1 and (K) PMP-4::mCherry staining. (L) Merge of images J and K. In yellow, colocalization of GFP::PTS-1 with PMP-4::mCherry. (M) DIC-Nomarsky images corresponding to the fluorescence images (n=30). Scale = 5 μm in each figure except for the expanded pictures in the squares, in which scale = 1 μm. The worms in the figures are oriented head to the left, dorsal face-up and only a portion of the central part of the body is depicted. (N) Dinitrophenol (DNP) protein levels in WT and pmp-4(ok396) animals at the L4 larval stage. The quantification of these blots by densitometry was performed and normalized to β-actin (n=4 pools of worms by condition). Relative total ROS levels (H2DCFDA) were measured by quantifying the fluorescence emission of the H2DCFDA probes in living animals in (O) WT (n=51), (P) pmp-4(ok396)(n=66) and (Q) daf-22(ok693) (n=40) L4 nematodes maintained in a liquid medium. Values are normalized to WT. Relative mitochondrial ROS levels in living animals in (R) WT (n=66), (S) pmp-4(ok396) (n=88) and (T) daf-22(ok693) (n=66) L4 nematodes quantified with MitoSox probes. Values are normalized to WT worms. Scale = 50 μm. (U) The thrashing behaviour of WT and pmp-4(ok396) nematodes was analysed in liquid medium at L4+7 days (n=20 animals/condition). Representative fluorescence images of GFP-labelled GABAergic neurons showing axonal abnormalities and quantitative analysis in living worms in (V) juIs76 [Punc-25::gfp] (n=20) and (W) pmp-4(ok396); juIs76 [Punc-25::gfp] (n=20) at L4+7 days. Scale = 25 μm. Data represent the mean ± standard deviation (SD). Statistical analysis was carried out with one-way ANOVA, followed by Tukey’s post hoc test (*P<0.05; **P<0.01; ***P<0.001) for D, O-S. Statistical analysis was carried out with Student’s t-test (*P<0.05; **P<0.01; ***P<0.001) for U-W.
Figure 2
Figure 2. pmp-4(ok396) worms display lipid droplet accumulation.
(A-P) At the L4 larval stage, WT and pmp-4(ok396) nematodes were fed or fasted for 24 h. (A-D) Bright field images of the posterior part of the worm stained with Sudan Black in (A) WT + FED (n=46), (B) WT + FASTING (n=60), (C) pmp-4(ok396) + FED (n=60), and (D) pmp-4(ok396) + FASTING (n=66). Lipids are evident as black droplets, labelled by a black arrow. Scale = 10 μm. Semi-quantitative analysis of the lipid droplets with a diameter >= 5 μm under the indicated conditions. (E-P) Localization of ATGL-1::GFP protein, driven by the atgl-1 promoter at L4, in (E-G) hjIs67 [Patgl-1::atgl-1::gfp] + FED, (H-J) hjIs67 [Patgl-1::atgl-1::gfp] + FASTING, (K-M) pmp-4(ok396); hjIs67 [Patgl-1::atgl-1::gfp] + FED and (N-P) pmp-4(ok396); hjIs67 [Patgl-1::atgl-1::gfp] + FASTING animals. (E) DIC-Nomarsky image and (F-G) GFP staining in WT. G is an enlarged image of F. (H) DIC-Nomarsky image and (I-J) GFP staining in WT after 24 h of fasting. J is an enlarged image of I. (K) DIC-Nomarsky image and (L-M) GFP staining in pmp-4(ok396). M is an enlarged image of L. (N) DIC-Nomarsky image and (O-P) GFP staining in pmp-4(ok396); hjIs67 [Patgl-1::atgl-1::gfp] after 24 h of fasting. P is an enlarged image of O. ATGL-1::GFP protein localized to the surface of large lipid droplets are indicated with white arrows (n=30 by conditions). The worms in the figures are oriented head to the left, dorsal face-up and only a portion of the central part of the body is depicted. Scale = 5 μM. Data represent the mean ± SD. Statistical analysis was carried out with two-way ANOVA, followed by Tukey’s post hoc test (*P<0.05; **P<0.01; ***P<0.001).
Figure 3
Figure 3. Mitochondrial dysfunction in pmp-4(ok396) animals.
WT and pmp-4(ok396) worms were incubated at the L4 larval stage with (A) the mitochondrial complex I inhibitor Paraquat (PQT) (n=51 to 54 animals by condition), the mitochondrial complex II inhibitors (B) 3-nitropropionic acid (3-NP) (n=15 to 20 animals by condition), (C) thenoyltrifluoroacetone (TTFA) (n=18 to 20 animals by condition), (D) the complex III inhibitor (antimycin A) (n=20 animals by condition) and (E) the complex IV inhibitor (sodium azide)(n=20 animals by condition). The lethality of the worms after the treatment was evaluated as described in the methodology. (F-Q). At L4, WT and pmp-4(ok396) nematodes were treated with CoQ (1 mg/ml) or MitoQ (5 μg/ml) for 7 days. Total ROS levels were measured by quantifying the fluorescence emission of the H2DCFDA probes in living animals in (F) WT (n=42), (G) pmp-4(ok396)(n=35), (H) WT + CoQ (n=32), (I) pmp-4(ok396) + CoQ (n=30), (J) WT + MitoQ (n=47), and (K) pmp-4(ok396) + MitoQ (n=32) animals at L4+7 days. Values are normalized to the untreated WT nematodes. Scale = 50 μm. Bright field images of the posterior part of the worm stained with Sudan Black in (L) WT (n=46), (M) pmp-4(ok396)(n=61), (N) WT + CoQ (n=60), (O) pmp-4(ok396) + CoQ (n=60), (P) WT + MitoQ (n=30), and (Q) pmp-4(ok396) + MitoQ (n=27) worms at L4+7 days. Lipids are evident as black droplets, labelled by a black arrow. Scale = 10 μm. Semi-quantitative analysis of the lipid droplets with a diameter >= 5 μm under the indicated conditions. Data represent the mean ± SD. Statistical analysis was carried out with Student’s t-test (*P<0.05; **P<0.01; ***P<0.001) for A-E. Statistical analysis was carried out with two-way ANOVA, followed by Tukey’s post hoc test (*P<0.05; **P<0.01; ***P<0.001) for F-Q.
Figure 4
Figure 4. Mitochondrial-targeted antioxidant rescue axonal abnormalities and locomotor dysfunction at old stages of development.
(A-G) At the L4 larval stages, WT and pmp-4(ok396) nematodes were treated with CoQ (1 mg/ml) or MitoQ (5 μg/ml) for 7 days. (A) The thrashing behaviour was carried out in WT and pmp-4(ok396) nematodes upon CoQ or MitoQ at L4+7 days (n=15 to 27 animals by condition). Representative fluorescence images showing axonal abnormalities and quantitative analysis at the indicated genotypes upon CoQ or MitoQ at L4+7 days in (B) juIs76 [Punc-25::gfp] (n=20), (C) pmp-4(ok396); juIs76 [Punc-25::gfp] (n=20), (D) juIs76 [Punc-25::gfp] + CoQ (n=18), (E)pmp-4(ok396); juIs76 [Punc-25::gfp] + CoQ (n=15), (F) juIs76 [Punc-25::gfp] + MitoQ (n=26) and (G) pmp-4(ok396; juIs76 [Punc-25::gfp]) + MitoQ (n=27). White asterisks indicate axonal abnormalities. All worms are oriented with the anterior end left and ventral side down. Scale = 25 μm. (H-N) At the L4 larval stage, juIs76 [Punc-25::gfp]and pmp-4(ok396); juIs76 [Punc-25::gfp] nematodes were treated with paraquat (PQT) (0.2 mM) and/or MitoQ (5 μg/ml) for 7 days. (H) The thrashing behaviour was analysed at stage L4+7 days in WT and pmp-4(ok396) nematodes upon PQT and/or MitoQ (n=20 to 31 animals by condition). Representative fluorescence images showing axonal abnormalities and quantitative analysis at stage L4+7 days in (I) juIs76 [Punc-25::gfp]) (n=29), (J) pmp-4(ok396); juIs76 [Punc-25::gfp] (n=31), (K) juIs76 [Punc-25::gfp] + PQT(n=25), (L) pmp-4(ok396); juIs76 [Punc-25::gfp] + PQT (n=20), (M) juIs76 [Punc-25::gfp] + PQT + MitoQ (n=21), (N) pmp-4(ok396; juIs76 [Punc-25::gfp] + PQT + MitoQ (n=28). Scale = 25μm. All worms are oriented with the anterior end left and ventral side down. Data represent the mean ± standard deviation (SD). Statistical analysis was carried out with two-way ANOVA, followed by Tukey’s post hoc test (*P<0.05; **P<0.01; ***P<0.001) for A-N.
Figure 5
Figure 5. Subcellular localization and tissue distribution of PMP-4
(A) mito::GFP was expressed under the control of the pan-neuronal promoter rgef-1 (Prgef-1) in WT animals (Ex129 [Prgef-1::mito::gfp]). Here, mitochondria located in all neurons are labelled with GFP. Next, worms were fixed and double immunostained against PMP-4 (red). Nuclei were counterstained with DAPI (blue) (n=30). Scale = 5 μm. (B) mCherry driven by the pmp-4 promoter was expressed in the GABAergic strain juIs76 [Punc-25::gfp], where GABAergic neurons are stained with GFP (juIs76 [Punc-25::gfp]; Ex074 [Ppmp-4::mCherry])(n=30). Scale = 5 μm. (C-D) PMP-4::mCherry driven by the pmp-4 promoter was expressed in a pan-neuronal strain where all neurons are stained with GFP (evIs111 [Prgef-1::gfp]; Ex067 [Ppmp-4::pmp-4::mCherry]) (n=30). Next, PMP-4::mCherry and GFP staining was observed in nematodes. Cell bodies (CB), NR: Nerve ring, H: hypodermis, I: intestine. Scale = 5μm. (E) PMP-4::GFP (Ex132 [Punc-25::pmp-4::gfp]) and (F) GFP::DAF-22 (Ex134 [Punc-25::gfp::daf-22]) under the control of a GABAergic promoter (Punc-25) were expressed in WT worms (n=30 by condition). (E) PMP-4::GFP and (F) GFP::DAF-22 staining was observed in nematodes. Scale = 1 μm. (G) mCherry driven by the pmp-4 promoter was expressed in glial-like cells strain nsIs105 [Phlh-17::gfp], where glial CEPsh cells are labelled with GFP (nsIs105 [Phlh-17::gfp]; Ex 136 [Ppmp-4::mCherry]) (n=30). Next, mCherry and GFP staining was observed in nematodes. Scale = 5 μm. (H) mCherry driven by the peroxisomal prx-5 promoter (Pprx-5) was expressed in the pan-neuronal strain evIs111 [Prgef-1::gfp], where all neurons are labelled with GFP (evIs111 [Prgef-1::gfp]; Ex146 [Pprx-5::mCherry]) (n=30). Next, mCherry and GFP staining were observed in nematodes. Scale = 5μm. We then used a construct containing PTS1 to target the peroxisomes. (I) GFP::PTS1 driven by a pan-neuronal promoter (Prgef-1) was expressed in WT worms (Ex070 [Prgef-1::gfp::PTS1]). Next, mitochondria were stained with Mitotracker probes, and GFP staining was visualized (n=30). Scale = 10 μm. (J) mCherry::PTS1 driven by a GABAergic promoter (Punc-25) and mito::GFP under the pan-neuronal promoter rgef-1 (Prgef-1) were co-expressed in WT animals (Ex218 [Punc-25::mCherry::PTS1 + Prgef-1::mito::gfp]). Next, mCherry and GFP staining were observed in nematodes (n=30). Scale = 5μm. (K) GFP::PTS1 driven by a hypodermal promoter (Pdpy-7) was expressed in WT worms (Ex090 [Pdpy-7::gfp::PTS1]). Next, mitochondria were stained with Mitotracker probes, and GFP staining was visualized (n=30). Scale = 10 μm. (L) mCherry::PTS1 driven by a hypodermal promoter (Pdpy-7) and mito::GFP under the pan-neuronal promoter rgef-1 (Prgef-1) were co-expressed in WT animals (Ex207 [Pdpy-7::mCherry::PTS1 + Prgef-1::mito::gfp]). Next, mCherry and GFP staining was observed in nematodes (n=30). Scale = 5 μm.
Figure 6
Figure 6. Specific PMP-4 expression in the hypodermis is essential to maintain axonal integrity and locomotion.
(A) Locomotion behaviour expressed as thrashes per minute at L4+7 days in juIs76 [Punc-25::gfp], pmp-4(ok396); juIs76 [Punc-25::gfp] and pmp-4(ok396; juIs76 [Punc-25::gfp]) animals where PMP-4::mCherry is expressed in hypodermis (pmp-4(ok396); juIs76 [Punc-25::gfp]; Ex177 [Pdpy-7::pmp-4::mCherry]), in intestine (pmp-4(ok396); juIs76 [Punc-25::gfp]; Ex151 [Pges-1::pmp-4::mCherry]) or in neurons (pmp-4(ok396); juIs76 [Punc-25::gfp]; Ex191 [Punc-25::pmp-4::mCherry]) (n= 19 to 23 animals by condition). Representative confocal pictures showing axonal damage and quantitative analysis in (B) juIs76 [Punc-25::gfp] (n=22), (C) pmp-4(ok396); juIs76 [Punc-25::gfp] animals (n=19), pmp-4(ok396) animals where PMP-4::mCherry is expressed in (D) hypodermis (pmp-4(ok396); juIs76 [Punc-25::gfp]; Ex177 [Pdpy-7::pmp-4::mCherry]) (n=23), (E) intestine (pmp-4(ok396); juIs76 [Punc-25::gfp]; Ex151 [Pges-l::pmp-4::mCherry]) (n=22) or (F) neurons (pmp-4(ok396); juIs76 [Punc-25::gfp]; Ex191 [Punc-25::pmp-4::mCherry]) (n=19). The red colour in all pictures corresponds to the strong expression in the pharynx of the co-injection marker Pmyo-2::mCherry. White asterisks label the axonal abnormalities. Worms are oriented head to the left and dorsal face-up. Scale = 25 μm. Data represent the mean ± standard deviation (SD). Statistical analysis was carried out with two-way ANOVA, followed by Tukey’s post hoc test (*P<0.05; **P<0.01; ***P<0.001).

Similar articles

Cited by

References

    1. Van Veldhoven PP, Baes M. Peroxisome deficient invertebrate and vertebrate animal models. Front Physiol. 2013;4:335. - PMC - PubMed
    1. Waterham HR, Ferdinandusse S, Wanders RJ. Human disorders of peroxisome metabolism and biogenesis. Biochim Biophys Acta. 2016;1863(5):922–33. - PubMed
    1. Moser AB, Fatemi A. Newborn Screening and Emerging Therapies for X-Linked Adrenoleukodystrophy. JAMA Neurol. 2018:e - PubMed
    1. van Roermund CW, Visser WF, Ijlst L, van Cruchten A, Boek M, Kulik W, Waterham HR, Wanders RJ. The human peroxisomal ABC half transporter ALDP functions as a homodimer and accepts acyl-CoA esters. Faseb J. 2008;22(12):4201–8. - PubMed
    1. Engelen M, Kemp S, Poll-The BT. X-linked adrenoleukodystrophy: pathogenesis and treatment. Curr Neurol Neurosci Rep. 2014;14(10):486. - PubMed

Publication types

MeSH terms

Substances